Ευκολία και λύσεις για μία καλύτερη καθημερινότητα!
PGA.3 Synthetic absorbable surgical suture of polyglycolic acid
| Code | Needle | Thread Length |
| 9623 | 16mm cutting 3/8 of circle triangular | 45cm |
| 9633 | 19mm cutting 3/8 of circle triangular | 75cm |
| 9643 | 24mm cutting 3/8 of circle triangular | 75cm |
| 9648 | 26mm cutting 3/8 of circle triangular | 75cm |
| 9143 | 26mm round 1/2 of circle atraumatic | 75cm |
| 9153 | 30mm round 1/2 of circle atraumatic | 75cm |
Manufactured in Greece by Medipac
PGA.3 Synthetic absorbable surgical suture of polyglycolic acid
It can generally be used for the approximation, retention in contact and/or convergence of soft tissues, even in ophthalmological operations. It is not indicated for the tissues of the central cardiovascular and central nervous system.
PGA surgical suture causes a minimal acute inflammatory reaction in tissues, which is followed by gradual encapsulation of the suture by fibrous connective tissue. Progressive loss of tensile strength and eventual absorption occurs by means of hydrolysis, where the polymer degrades to glycolic acid which is subsequently absorbed and metabolized by the body.
During the absorption of the PGA suture initially a loss of its strength is observed without a significant loss of its mass.
The PGA suture has a residual strength of more than 75% of the European Pharmacopoeia requirement at the end of the second week after its implantation and more than 35% approximately at the end of the third week.
The absorption of the suture is completed within 50 – 90 days.
| Code | Needle | Thread Length |
| 9623 | 16mm cutting 3/8 of circle triangular | 45cm |
| 9633 | 19mm cutting 3/8 of circle triangular | 75cm |
| 9643 | 24mm cutting 3/8 of circle triangular | 75cm |
| 9648 | 26mm cutting 3/8 of circle triangular | 75cm |
| 9143 | 26mm round 1/2 of circle atraumatic | 75cm |
| 9153 | 30mm round 1/2 of circle atraumatic | 75cm |
Manufactured in Greece by Medipac
Description
PGA.3 Synthetic absorbable surgical suture of polyglycolic acid
It can generally be used for the approximation, retention in contact and/or convergence of soft tissues, even in ophthalmological operations. It is not indicated for the tissues of the central cardiovascular and central nervous system.
PGA surgical suture causes a minimal acute inflammatory reaction in tissues, which is followed by gradual encapsulation of the suture by fibrous connective tissue. Progressive loss of tensile strength and eventual absorption occurs by means of hydrolysis, where the polymer degrades to glycolic acid which is subsequently absorbed and metabolized by the body.
During the absorption of the PGA suture initially a loss of its strength is observed without a significant loss of its mass.
The PGA suture has a residual strength of more than 75% of the European Pharmacopoeia requirement at the end of the second week after its implantation and more than 35% approximately at the end of the third week.
The absorption of the suture is completed within 50 – 90 days.
| Code | Needle | Thread Length |
| 9623 | 16mm cutting 3/8 of circle triangular | 45cm |
| 9633 | 19mm cutting 3/8 of circle triangular | 75cm |
| 9643 | 24mm cutting 3/8 of circle triangular | 75cm |
| 9648 | 26mm cutting 3/8 of circle triangular | 75cm |
| 9143 | 26mm round 1/2 of circle atraumatic | 75cm |
| 9153 | 30mm round 1/2 of circle atraumatic | 75cm |
Manufactured in Greece by Medipac
